瑞舒伐他汀联合依折麦布治疗冠心病急性心肌梗死的临床观察

Clinical Observation of Rosuvastatin Combined with Ezetimibe in the Treatment of Acute Myocardial Infarction of Coronary Heart Disease Patients

目的：观察瑞舒伐他汀联合依折麦布治疗冠心病急性心肌梗死的疗效及安全性。方法：将84例冠心病急性心肌梗死患者按随机数字表法分为治疗组和对照组,各42例。对照组患者口服依折麦布片10 mg,qd;治疗组患者在对照组基础上加服瑞舒伐他汀片10-40 mg,qd。两组均治疗4周。观察两组患者临床疗效及治疗前后左室射血分数（LVEF）、左室舒张末期容积（LVEDV）、肌红蛋白、C反应蛋白（CRP）、髓过氧化物酶（MPO）、同型半胱氨酸（Hcy）水平变化,并记录治疗期间不良反应发生情况。结果：治疗组患者总有效率为90.48%,显著高于对照组患者的71.43%,差异有统计学意义（P〈0.05）;两组患者治疗后LVEF水平明显升高,且治疗组高于对照组,差异均有统计学意义（P〈0.05）;两组患者治疗后LVEDV、肌红蛋白、CRP、MPO、Hcy水平明显降低,且治疗组低于对照组,差异均有统计学意义（P〈0.05）;两组患者治疗期间均未见明显不良反应发生。结论：瑞舒伐他汀联合依折麦布治疗冠心病急性心肌梗死患者疗效显著,可明显改善患者LVEF、LVEDV、肌红蛋白、CRP、MPO、Hcy的水平,且安全性较高。

OBJECTIVE：To observe therapeutic efficacy and safety of rosuvastatin combined with ezetimibe in the treatment of acute myocardial infarction（AMI） of coronary heart disease patients. METHODS：84 coronary heart disease patients with AMI were randomly divided into treatment group and control group with 42 cases in each group. Control group were treated with Ezetimibe tablets 10 mg,qd. Treatment group were additionally treated with Rosuvastatin tablets 10-40 mg,qd,on the basis of control group. Both groups received 4 weeks of treatment. Clinical efficacy was observed in 2 groups,and the changes of LVEF,LVEDV,myohemoglobin,CRP,MPO and Hcy were also observed before and after treatment. The occurrence of ADR was recorded during treatment. RESULTS：The total effective rate of treatment group（90.48%） was significantly higher than that of control group（71.43%）,with statistical significance（P〈0.05）;after treatment,LVEF level in both groups were obviously increased,and the treatment group was higher than the control group;LVEDV level,myohemoglobin,CRP,MPO and Hcy in both groups were obvious decreased in 2 groups after treatment,and the treatment group was lower than the control group,with statistical significance（P〈0.05）. No serious ADR was found in 2 groups during treatment. CONCLUSIONS：The clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of AMI of coronary heart disease patients,can improve LVEF,LVEDV,myohemoglobin,CRP,MPO and Hcy levels significantly,with good safety.